ScienceExplain

Why New Psychiatric Treatments Are Hard to Develop

Intermediate

1. Quick Summary

Diagnostic categories group symptoms, not causes. Two people with the same diagnosis may have different underlying biology and different treatment responses.

Why New Psychiatric Treatments Are Hard to Develop
A network: connected nodes passing things along.

Measurement relies on rating scales and clinical judgement, which introduces variability that makes small effects hard to detect.

Several drug classes were found partly by observation rather than design, and the mechanism of several effective treatments remains debated.

2. What It Means

Heterogeneity within a diagnosis is the core problem. A trial testing one mechanism across a heterogeneous group dilutes any benefit that exists in a subgroup.

Placebo response is substantial and variable. High and inconsistent placebo responses in psychiatric trials reduce the apparent effect of active treatment.

Outcome measures are usually symptom scales. Their reliability depends on training and consistency, and improvements may not map onto functional change in daily life.

Mechanistic models have had limited predictive success. Compounds designed against a hypothesised target have often failed despite strong preclinical rationale.

3. Why It Happens

The biology is distributed. Brain function emerges from networks rather than from a single measurable marker, so there is no equivalent of a blood test for most conditions.

Animal models capture limited aspects. Behaviour in rodents cannot represent the full range of human experience, so translation fails at a high rate.

The blood-brain barrier restricts compounds, and central nervous system drug development has historically had longer timelines and higher attrition than other areas.

Long-term outcomes require long trials. Conditions vary over time and spontaneous improvement occurs, so separating treatment effect from natural course needs duration and controls.

Diagnostic boundaries are not sharp. Symptoms overlap between categories, so a treatment targeting one may help people labelled with another, complicating trial enrolment.

4. Real Examples

Research frameworks aimed at identifying measurable dimensions rather than categories attempt to address heterogeneity directly, though their clinical utility is still being established.

Large-scale genetics has identified many variants of small effect rather than single causes, consistent with a highly polygenic picture.

Brain imaging has produced reproducible group differences but few measures reliable enough for individual diagnosis or treatment selection.

Psychological treatments show comparable effect sizes to medication for several conditions, and combining them sometimes outperforms either alone.

5. How It Affects Us

People with treatment-resistant conditions are underserved, which is why failure of existing options motivates the search for new mechanisms.

Expectation and context influence outcomes more here than in many areas of medicine, affecting both trial results and clinical practice.

Investment has shifted away from some traditional mechanisms and toward others, following both scientific and commercial considerations.

Access to non-drug treatments is uneven, so what dominates care often reflects service availability rather than comparative effectiveness.

6. Key Takeaways

  • Diagnoses describe symptoms, not mechanisms, and that shapes every stage of development.
  • Heterogeneity and placebo response make effects hard to demonstrate even when they exist.
  • Translation from animal models has been particularly unreliable here.
  • Effect sizes should be read alongside what they mean functionally, not only statistically.